Cleveland BioLabs (NASDAQ: CBLI) is one of 186 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it compare to its peers? We will compare Cleveland BioLabs to related businesses based on the strength of its earnings, analyst recommendations, dividends, valuation, profitability, risk and institutional ownership.

Risk & Volatility

Cleveland BioLabs has a beta of -0.32, indicating that its share price is 132% less volatile than the S&P 500. Comparatively, Cleveland BioLabs’ peers have a beta of 1.54, indicating that their average share price is 54% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Cleveland BioLabs and its peers, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cleveland BioLabs 0 0 0 0 N/A
Cleveland BioLabs Competitors 530 2400 6579 123 2.65

As a group, “Biotechnology & Medical Research” companies have a potential upside of 17.42%. Given Cleveland BioLabs’ peers higher probable upside, analysts clearly believe Cleveland BioLabs has less favorable growth aspects than its peers.

Institutional and Insider Ownership

4.4% of Cleveland BioLabs shares are held by institutional investors. Comparatively, 49.8% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 2.4% of Cleveland BioLabs shares are held by insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Cleveland BioLabs and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cleveland BioLabs -472.44% -91.87% -73.83%
Cleveland BioLabs Competitors -3,341.99% -537.73% -40.09%

Earnings and Valuation

This table compares Cleveland BioLabs and its peers top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Cleveland BioLabs $3.52 million -$2.65 million -2.89
Cleveland BioLabs Competitors $217.29 million -$39.39 million -74.38

Cleveland BioLabs’ peers have higher revenue, but lower earnings than Cleveland BioLabs. Cleveland BioLabs is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Summary

Cleveland BioLabs peers beat Cleveland BioLabs on 6 of the 9 factors compared.

Cleveland BioLabs Company Profile

Cleveland BioLabs, Inc. (CBLI) is a biopharmaceutical company. The Company is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. Its other products include CBLB612, Mobilan and CBL0137. CBLB612 is a compound based upon a natural activator of another tissue-specific component of the innate immune system, the toll-like receptor 2 (TLR2)/ toll-like receptor 6 (TLR6) heterodimeric receptor. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. CBL0137 is a small molecule with a multi-targeted mechanism of action that may be useful for the treatment of various types of cancer.

Receive News & Ratings for Cleveland BioLabs Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cleveland BioLabs Inc. and related companies with MarketBeat.com's FREE daily email newsletter.